Uncontrolled asthma: assessment and management
You must score at least 70% in this module to pass. Ensure you have read ‘Uncontrolled asthma: assessment and management’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
Quiz Summary
0 of 15 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 15 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Current
- Review
- Answered
- Correct
- Incorrect
- Question 1 of 15
1. Question
How many people in the UK suffer from severe asthma?
CorrectIncorrect - Question 2 of 15
2. Question
Which of the following is not a symptom of uncontrolled asthma?
CorrectIncorrect - Question 3 of 15
3. Question
Which of the following factors may contribute to a patient’s uncontrolled asthma?
CorrectIncorrect - Question 4 of 15
4. Question
Which of the following indicators can be used to assess patient adherence to treatment?
CorrectIncorrect - Question 5 of 15
5. Question
How many weeks should a 200-dose salbutamol pressurised metered dose inhaler be expected to last?
CorrectIncorrect - Question 6 of 15
6. Question
Peak expiratory flow (PEF) is measured to assess asthma control. What percentage of predicted or best PEF represents normal lung function?
CorrectIncorrect - Question 7 of 15
7. Question
Why is it good practice to prescribe inhalers by brand name?
CorrectIncorrect - Question 8 of 15
8. Question
Long-acting beta-2 agonists (LABAs) and leukotriene receptor antagonists (LTRAs) are both effective add-on therapies for adults with uncontrolled asthma on low dose inhaled corticosteroids (ICS) — and children on very low dose ICS. Why does the National Institute for Health and Care Excellence (NICE) recommend LTRAs over LABAs?
CorrectIncorrect - Question 9 of 15
9. Question
What has the Medicines and Healthcare products Regulatory Agency highlighted as a risk of using the leukotriene receptor antagonist montelukast?
CorrectIncorrect - Question 10 of 15
10. Question
If asthma remains uncontrolled despite low dose inhaled corticosteroids (ICS) with long-acting beta-2 agonists (LABAs), ICS doses can be increased. Which of the following represents a high dose in adults of the Fostair metered dose ICS/LABA combination inhaler?
CorrectIncorrect - Question 11 of 15
11. Question
Single inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination inhalers can be used for maintenance and reliever therapy. Which of the following combinations is licensed for this use?
CorrectIncorrect - Question 12 of 15
12. Question
The addition of which medication to an inhaled corticosteroid/long-acting beta-2 agonist regime in patients with severe asthma requires monitoring every 6–12 months?
CorrectIncorrect - Question 13 of 15
13. Question
Which of the following patients would be classified as having severe asthma?
CorrectIncorrect - Question 14 of 15
14. Question
Once asthma control has been achieved, patients should be stepped down to the lowest effective doses of their medications. How frequently should stepping down occur at this stage?
CorrectIncorrect - Question 15 of 15
15. Question
Which class of medication is contraindicated against inhaled steroids?
CorrectIncorrect